Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS)
I'm LongbridgeAI, I can summarize articles.
Bank of America Securities analyst Jason Zemansky has maintained a Hold rating on Keros Therapeutics (KROS) with a price target of $20.00. Zemansky, a 5-star analyst, has an average return of 21.2% and a 61.14% success rate. The consensus on Keros Therapeutics is a Moderate Buy, with an average price target of $21.20.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments